IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-49784-y.html
   My bibliography  Save this article

Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

Author

Listed:
  • Edurne San José-Enériz

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Naroa Gimenez-Camino

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Obdulia Rabal

    (Universidad de Navarra)

  • Leire Garate

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Estibaliz Miranda

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Nahia Gómez-Echarte

    (Universidad de Navarra, IDISNA, CCUN)

  • Fernando García

    (Unidad de Proteómica, Centro Nacional de Investigaciones Oncológicas (CNIO))

  • Stella Charalampopoulou

    (Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS))

  • Elena Sáez

    (Universidad de Navarra)

  • Amaia Vilas-Zornoza

    (Universidad de Navarra, IDISNA, CCUN)

  • Patxi San Martín-Uriz

    (Universidad de Navarra, IDISNA, CCUN)

  • Luis V. Valcárcel

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Universidad de Navarra)

  • Naroa Barrena

    (Universidad de Navarra)

  • Diego Alignani

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Luis Esteban Tamariz-Amador

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Clínica Universidad de Navarra, and CCUN, Universidad de Navarra)

  • Ana Pérez-Ruiz

    (Universidad de Navarra, IDISNA)

  • Sebastian Hilscher

    (Martin-Luther-University Halle-Wittenberg
    Martin-Luther-University Halle-Wittenberg)

  • Mike Schutkowski

    (Martin-Luther-University Halle-Wittenberg
    Martin-Luther-University Halle-Wittenberg)

  • Ana Alfonso-Pierola

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Clínica Universidad de Navarra, and CCUN, Universidad de Navarra)

  • Nicolás Martinez-Calle

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Clínica Universidad de Navarra, and CCUN, Universidad de Navarra)

  • María José Larrayoz

    (Universidad de Navarra)

  • Bruno Paiva

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • María José Calasanz

    (Universidad de Navarra)

  • Javier Muñoz

    (Biocruces Bizkaia Health Research Institute
    Basque Foundation for Science)

  • Marta Isasa

    (Unidad de Proteómica, Centro Nacional de Investigaciones Oncológicas (CNIO))

  • José Ignacio Martin-Subero

    (Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS)
    Universitat de Barcelona
    Institució Catalana de Recerca i Estudis Avançats (ICREA))

  • Antonio Pineda-Lucena

    (Universidad de Navarra)

  • Julen Oyarzabal

    (Universidad de Navarra)

  • Xabier Agirre

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC))

  • Felipe Prósper

    (Universidad de Navarra, IDISNA, CCUN
    Centro de Investigación Biomédica en Red Cáncer (CIBERONC)
    Clínica Universidad de Navarra, and CCUN, Universidad de Navarra)

Abstract

Despite the development of novel therapies for acute myeloid leukemia, outcomes remain poor for most patients, and therapeutic improvements are an urgent unmet need. Although treatment regimens promoting differentiation have succeeded in the treatment of acute promyelocytic leukemia, their role in other acute myeloid leukemia subtypes needs to be explored. Here we identify and characterize two lysine deacetylase inhibitors, CM-444 and CM-1758, exhibiting the capacity to promote myeloid differentiation in all acute myeloid leukemia subtypes at low non-cytotoxic doses, unlike other commercial histone deacetylase inhibitors. Analyzing the acetylome after CM-444 and CM-1758 treatment reveals modulation of non-histone proteins involved in the enhancer–promoter chromatin regulatory complex, including bromodomain proteins. This acetylation is essential for enhancing the expression of key transcription factors directly involved in the differentiation therapy induced by CM-444/CM-1758 in acute myeloid leukemia. In summary, these compounds may represent effective differentiation-based therapeutic agents across acute myeloid leukemia subtypes with a potential mechanism for the treatment of acute myeloid leukemia.

Suggested Citation

  • Edurne San José-Enériz & Naroa Gimenez-Camino & Obdulia Rabal & Leire Garate & Estibaliz Miranda & Nahia Gómez-Echarte & Fernando García & Stella Charalampopoulou & Elena Sáez & Amaia Vilas-Zornoza & , 2024. "Epigenetic-based differentiation therapy for Acute Myeloid Leukemia," Nature Communications, Nature, vol. 15(1), pages 1-23, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49784-y
    DOI: 10.1038/s41467-024-49784-y
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-49784-y
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-49784-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Rashmi R. Shah, 2019. "Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology," Drug Safety, Springer, vol. 42(2), pages 235-245, February.
    2. Henry E. Pelish & Brian B. Liau & Ioana I. Nitulescu & Anupong Tangpeerachaikul & Zachary C. Poss & Diogo H. Da Silva & Brittany T. Caruso & Alexander Arefolov & Olugbeminiyi Fadeyi & Amanda L. Christ, 2015. "Mediator kinase inhibition further activates super-enhancer-associated genes in AML," Nature, Nature, vol. 526(7572), pages 273-276, October.
    3. Johannes Zuber & Junwei Shi & Eric Wang & Amy R. Rappaport & Harald Herrmann & Edward A. Sison & Daniel Magoon & Jun Qi & Katharina Blatt & Mark Wunderlich & Meredith J. Taylor & Christopher Johns & A, 2011. "RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia," Nature, Nature, vol. 478(7370), pages 524-528, October.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Rashmi R. Shah & Giuseppe Curigliano, 2019. "Safety of Novel Targeted Therapies in Oncology," Drug Safety, Springer, vol. 42(2), pages 157-158, February.
    2. Shaela Wright & Xujie Zhao & Wojciech Rosikiewicz & Shelby Mryncza & Judith Hyle & Wenjie Qi & Zhenling Liu & Siqi Yi & Yong Cheng & Beisi Xu & Chunliang Li, 2023. "Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens," Nature Communications, Nature, vol. 14(1), pages 1-15, December.
    3. Yansheng Zhai & Xiaoyan Huang & Keren Zhang & Yuchen Huang & Yanlong Jiang & Jingwei Cui & Zhe Zhang & Cookson K. C. Chiu & Weiye Zhong & Gang Li, 2022. "Spatiotemporal-resolved protein networks profiling with photoactivation dependent proximity labeling," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    4. Stella Amanda & Tze King Tan & Jolynn Zu Lin Ong & Madelaine Skolastika Theardy & Regina Wan Ju Wong & Xiao Zi Huang & Muhammad Zulfaqar Ali & Yan Li & Zhiyuan Gong & Hiroshi Inagaki & Ee Yong Foo & B, 2022. "IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-49784-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.